References

Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors

10.1186/s40662-016-0063-5 · 2016 · External reference

The prevalence of age-related eye diseases and visual impairment in aging: current estimates

10.1167/iovs.13-12789 · 2013 · External reference

Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity

10.1016/s0161-6420(97)30079-7 · 1997 · External reference

Cone- and rod-mediated dark adaptation impairment in age-related maculopathy

10.1016/j.ophtha.2006.12.023 · 2007 · External reference

Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration

10.1016/j.ophtha.2008.03.009 · 2008 · External reference

Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration

10.1001/jamaophthalmol.2014.5963 · 2015 · External reference

Longitudinal study of visual function in dry age-related macular degeneration at 12 months

10.1016/j.oret.2019.03.010 · 2019 · External reference

Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy

10.1167/iovs.05-1222 · 2006 · External reference

Natural history of geographic atrophy secondary to age-related macular degeneration: results from the prospective Proxima A and B clinical trials

10.1016/j.ophtha.2019.12.009 · 2020 · External reference

Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration

10.1016/j.ophtha.2017.11.036 · 2018 · External reference

Mitochondria: potential targets for protection in age-related macular degeneration

10.1007/978-3-319-75402-4_2 · 2018 · External reference

Retinal pigment epithelium response to oxidant injury in the pathogenesis of early age-related macular degeneration

10.1016/j.mam.2012.04.006 · 2012 · External reference

Investigating mitochondria as a target for treating age-related macular degeneration

10.1523/jneurosci.0190-15.2015 · 2015 · External reference

Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration

10.1016/j.exer.2016.01.018 · 2016 · External reference

Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity

10.1167/iovs.04-1224 · 2005 · External reference

Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration

10.1016/j.preteyeres.2020.100858 · 2020 · External reference

Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration

10.1167/iovs.10-5429 · 2010 · External reference

Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness

10.1016/s0161-6420(99)90356-1 · 1999 · External reference

Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation

10.1016/s0002-9394(99)00057-4 · 1999 · External reference

Ocular pathology of MELAS syndrome with mitochondrial DNA nucleotide 3243 point mutation

10.1016/s0161-6420(13)31404-3 · 1993 · External reference

The role of mitochondria in AMD: current knowledge and future applications

10.4103/jovr.jovr_182_17 · 2017 · External reference

Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide

10.1007/s10741-020-10031-3 · 2021 · External reference

Mitochondrial reactive oxygen species production and elimination

10.1016/j.yjmcc.2014.03.011 · 2014 · External reference

Elamipretide protects RPE and improves mitochondrial function in models of AMD

2017 · External reference

Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis

10.1111/bph.12468 · 2014 · External reference

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

10.1111/bph.12461 · 2014 · External reference

Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the mito-reparative drug MTP-131

2016 · External reference

Phase 1 clinical trial of Elamipretide in intermediate age-related macular degeneration and high-risk drusen ReCLAIM High-Risk Drusen Study

2021 · External reference

MultipleTesting.com: a tool for life science researchers for multiple hypothesis testing correction

10.1371/journal.pone.0245824 · 2021 · External reference

The progression of geographic atrophy secondary to age-related macular degeneration

10.1016/j.ophtha.2017.08.038 · 2018 · External reference

The burden of age-related macular degeneration: a value-based medicine analysis

2005 · External reference

The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD

10.1016/j.preteyeres.2017.03.002 · 2017 · External reference

Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints

10.1016/j.ajo.2018.02.012 · 2018 · External reference

Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD

10.1167/iovs.05-0719 · 2006 · External reference

Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E

10.1167/iovs.03-0910 · 2004 · External reference

The mitochondria-targeted peptide MTP-131 prevents hydroquinone-mediated persistent injury phenotype in cultured retinal pigment epithelium cells

2015 · External reference

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy

10.1212/wnl.0000000000005255 · 2018 · External reference

Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial: effects of elamipretide in heart failure

10.1016/j.cardfail.2020.02.001 · 2020 · External reference

Novel mitochondria-targeting peptide in heart failure treatment

2017 · External reference

Intrasession test-retest variability of microperimetry in age-related macular degeneration

10.1167/iovs.13-12617 · 2013 · External reference

C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial

10.1016/j.ophtha.2020.08.027 · 2021 · External reference

Visual function measures in early and intermediate age-related macular degeneration

10.1097/iae.0000000000001002 · 2016 · External reference

Low-luminance visual acuity and microperimetry in age-related macular degeneration

10.1016/j.ophtha.2014.02.005 · 2014 · External reference

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study

10.1016/j.ophtha.2013.09.044 · 2014 · External reference

OCT minimum intensity as a predictor of geographic atrophy enlargement

10.1167/iovs.13-13199 · 2014 · External reference